Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 August 2020) | Viewed by 8867
Special Issue Editor
Interests: adenocarcinoma of the colon and rectum
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In recent decades, the treatment for metastatic colorectal cancer (mCRC) has remarkably progressed with the advent of biological agents. Nowadays the median survival time of mCRC patients is over 30 months. Under such circumstances, it becomes a key issue which biological agent is a preferred treatment, especially for first-line treatment of mCRC patients with RAS wild-type tumor. For unresectable diseases, preferred treatment depends on treatment goal; patients should be treated to seek for maximum shrinkage, or treatment duration. If the former, anti-EGFR mab might be a preferred option in terms of depth of response. If the latter, bevacizumab (BEV) might be preferred in terms of maintenance therapy.
For unresectable liver limited diseases, a similar strategy for treatment can be recommended. There are several types of liver metastases (LM). If LM is bulky and unresectable, a tumor shrinkage is supposed to be needed so that LM can be converted to be resectable. If LM is disseminated and unresectable, a pathological effect is supposed to be to prevent recurrence after liver resection. If the former, anti-EGFR mab might be preferred and if the latter, bevacizumab might be better, considering characteristics of biological agents. We have to consider a preferred treatment option according to a real clinical case.
In ATOM trial, a randomized phase II study of mFOLFOX6 plus BEV versus mFOLFOX6 plus cetuximab (CET) for liver-limited metastatic colorectal cancer that is unsuitable for upfront resection, BEV and CET showed a similar efficacy in PFS and liver resection rate, though greater tumor shrinkage was observed in CET group.
Prof. Dr. Hiroyuki Uetake
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Perioperative combination chemotherapy
- bevacizumab
- anti-EGFR
- depth of response
- pathological response
- conversion
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
